Royalty Pharma plc RPRX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 709.06% | -93.93% | 37.57% | -24.63% | 783.32% |
| Total Depreciation and Amortization | -5.64% | 10.50% | -2.09% | -6.34% | -7.40% |
| Total Amortization of Deferred Charges | 6.97% | 0.80% | 1.70% | -3.85% | -1.58% |
| Total Other Non-Cash Items | -43.40% | 52.44% | -16.66% | 14.63% | 6.95% |
| Change in Net Operating Assets | -9.19% | 7.95% | -13.42% | 16.01% | 7.12% |
| Cash from Operations | -5.82% | 1.42% | -13.17% | 17.72% | 93.03% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | 100.00% | 99.70% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -24.35% | 51.93% | 43.63% | 11.51% | -302.91% |
| Cash from Investing | -24.35% | 51.93% | 43.63% | 11.53% | -207.17% |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | -- | -- | -- | 100.00% | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -93.40% | 10.89% | 37.79% | 45.02% | 49.76% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -0.19% | -0.41% | -10.76% | 1.02% | -2.22% |
| Other Financing Activities | -2.99% | -4.67% | 5.32% | 16.82% | -21.90% |
| Cash from Financing | -155.81% | -0.18% | 8.99% | -153.24% | 210.82% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -232.24% | 798.40% | 89.91% | -204.30% | 167.36% |